ReleaseWire Connect

Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) innovuspharma.com (OTCQB:INNV) a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Sothema Laboratories, ("Sothema") received marketing authorization for Zestra® in the United Arab Emirates (the "UAE").

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it acquired the worldwide rights to the Fluticare(TM) brand (Fluticasone propionate nasal spray) from Novalere FP., Inc. ("Novalere") through a merger.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti®, a patented and clinically proven product to support male reproductive health and sperm quality, in the U.S. and Canada.

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB:INNV) announced today it has expanded its exclusive marketing and distribution agreement with Tramorgan Limited ("Tramorgan") ,and granted to Tramorgan additional rights to market and sell Innovus Pharma's oral dietary supplement to promote sexual and cognitive health, Vesele® in the United Kingdom ("UK"). Under the agreement, Innovus is eligible to receive up to $13 million dollars in sales milestone payments plus fifty percent (50%) royalties based on Tramorgan's sales of Vesele® in the UK.

Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a provider for over the counter men's and women's health products, will release its third quarter 2014 financial results on Friday, November 14, 2014 when it expects to file its Form 10-Q for the 2014 third quarter.